Rod shaped nanocrystals exhibit superior in vitro dissolution and in vivo bioavailability over spherical like nanocrystals: A case study of lovastatin

Colloids and Surfaces B: Biointerfaces

Volumn 128, Issue , 2015, Pages 410-418

  Guo, Mengran ^a   Fu, Qiang ^a   Wu, Chunnuan ^a   Guo, Zhibin ^a   Li, Mo ^b   Sun, Jin ^a   He, Zhonggui ^a   Yang, Li ^a  

^a SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

^b Liaoning Institute for Drug Control   (China)

Author keywords

In vitro characterization; Nanocrystals; Oral bioavailability; Rod shaped nanocrystals; Spherical like nanocrystals

Indexed keywords

ATOMIC FORCE MICROSCOPY; BIOCHEMISTRY; CRYSTALLINE MATERIALS; DIFFERENTIAL SCANNING CALORIMETRY; DISSOLUTION; FLUID DYNAMICS; FOURIER TRANSFORM INFRARED SPECTROSCOPY; HYDRODYNAMICS; INFRARED DRYING; SCANNING ELECTRON MICROSCOPY; SPHERES; TRANSMISSION ELECTRON MICROSCOPY;

HYDRODYNAMIC DIAMETER; IN-VITRO; IN-VITRO DISSOLUTION; ORAL ADMINISTRATION; ORAL BIOAVAILABILITIES; PHARMACOKINETIC STUDIES; POLYDISPERSITY INDICES; ROD-SHAPED;

NANOCRYSTALS;

HYPOCHOLESTEROLEMIC AGENT; MEVINOLIN; NANOPARTICLE;

ANIMAL; BIOAVAILABILITY; BLOOD; CHEMISTRY; DOG; FREEZE DRYING; ORAL DRUG ADMINISTRATION; PARTICLE SIZE; SOLUBILITY; ULTRASOUND; ULTRASTRUCTURE;

ADMINISTRATION, ORAL; ANIMALS; ANTICHOLESTEREMIC AGENTS; BIOLOGICAL AVAILABILITY; DOGS; FREEZE DRYING; LOVASTATIN; NANOPARTICLES; PARTICLE SIZE; SOLUBILITY; SONICATION;

EID: 84939995453     PISSN: 09277765     EISSN: 18734367     Source Type: Journal    
DOI: 10.1016/j.colsurfb.2015.02.039     Document Type: Article

References (51)

1. Kesisoglou F., Wu Y. Understanding the effect of API properties on bioavailability through absorption modeling. AAPS J. 2008, 10:516-525.
2. Merisko-Liversidge E., Liversidge G.G., Cooper E.R. Nanosizing: a formulation approach for poorly-water-soluble compounds. Eur. J. Pharm. Sci. 2003, 18:113-120.
3. Seedher N., Kanojia M. Co-solvent solubilization of some poorly-soluble antidiabetic drugs. Pharm. Dev. Technol. 2009, 14:185-192.
4. Chiou W.L., Riegelman S. Pharmaceutical applications of solid dispersion systems. J. Pharm. Sci. 1971, 60:1281-1302.
5. Serajuddin A.T. Solid dispersion of poorly water-soluble drugs: early promises, subsequent problems, and recent breakthroughs. J. Pharm. Sci. 1999, 88:1058-1066.
6. Stella V.J., Rajewski R.A. Cyclodextrins: their future in drug formulation and delivery. Pharm. Res. 1997, 14:556-567.
7. Anton N., Vandamme T.F. Nano-emulsions and micro-emulsions: clarifications of the critical differences. Pharm. Res. 2011, 28:978-985.
8. Vemuri S., Rhodes C.T. Preparation and characterization of liposomes as therapeutic delivery systems: a review. Pharm. Acta Helv. 1995, 70:95-111.
9. Jones M., Leroux J. Polymeric micelles-a new generation of colloidal drug carriers. Eur. J. Pharm. Biopharm. 1999, 48:101-111.
10. Patravale V.B., Date A.A., Kulkarni R.M. Nanosuspensions: a promising drug delivery strategy. J. Pharm. Pharmacol. 2004, 56:827-840.
11. Rabinow B.E. Nanosuspensions in drug delivery. Nat. Rev. Drug Discov. 2004, 3:785-796.
12. Jinno J., Kamada N., Miyake M., Yamada K., Mukai T., Odomi M., Toguchi H., Liversidge G.G., Higaki K., Kimura T. Effect of hydrodynamic diameter reduction on dissolution and oral absorption of a poorly water-soluble drug, cilostazol, in beagle dogs. J. Control. Release 2006, 111:56-64.
13. Muller R.H., Jacobs C. Buparvaquone mucoadhesive nanosuspension: preparation, optimisation and long-term stability. Int. J. Pharm. 2002, 237:151-161.
14. Lennernas H., Fager G. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences. Clin. Pharmacokinet. 1997, 32:403-425.
15. Fu Q., Sun J., Zhang D., Li M., Wang Y., Ling G., Liu X., Sun Y., Sui X., Luo C., Sun L., Han X., Lian H., Zhu M., Wang S., He Z. Nimodipine nanocrystals for oral bioavailability improvement: preparation, characterization and pharmacokinetic studies. Colloids Surf. B Biointerfaces 2013, 109:161-166.
16. Jiang T., Han N., Zhao B., Xie Y., Wang S. Enhanced dissolution rate and oral bioavailability of simvastatin nanocrystal prepared by sonoprecipitation. Drug Dev. Ind. Pharm. 2012, 38:1230-1239.
17. Ige P.P., Baria R.K., Gattani S.G. Fabrication of fenofibrate nanocrystals by probe sonication method for enhancement of dissolution rate and oral bioavailability. Colloids Surf. B Biointerfaces 2013, 108:366-373.
18. Hong C., Dang Y., Lin G., Yao Y., Li G., Ji G., Shen H., Xie Y. Effects of stabilizing agents on the development of myricetin nanosuspension and its characterization: an in vitro and in vivo evaluation. Int. J. Pharm. 2014, 477:251-260.
19. Rabinow B., Kipp J., Papadopoulos P., Wong J., Glosson J., Gass J., Sun C.S., Wielgos T., White R., Cook C., Barker K., Wood K. Itraconazole IV nanosuspension enhances efficacy through altered pharmacokinetics in the rat. Int. J. Pharm. 2007, 339:251-260.
20. Liu P., Rong X., Laru J., van Veen B., Kiesvaara J., Hirvonen J., Laaksonen T., Peltonen L. Nanosuspensions of poorly soluble drugs: preparation and development by wet milling. Int. J. Pharm. 2011, 411:215-222.
21. Ghosh I., Bose S., Vippagunta R., Harmon F. Nanosuspension for improving the bioavailability of a poorly soluble drug and screening of stabilizing agents to inhibit crystal growth. Int. J. Pharm. 2011, 409:260-268.
22. Yang X., Miao X., Cao F., Li S., Ai N., Chang Q., Lee S.M., Zheng Y. Nanosuspension development of scutellarein as an active and rapid orally absorbed precursor of its BCS class IV glycoside scutellarin. J. Pharm. Sci. 2014, 103:3576-3584.
23. Li W., Yang Y., Tian Y., Xu X., Chen Y., Mu L., Zhang Y., Fang L. Preparation and in vitro/in vivo evaluation of revaprazan hydrochloride nanosuspension. Int. J. Pharm. 2011, 408:157-162.
24. Gao L., Liu G., Kang J., Niu M., Wang Z., Wang H., Ma J., Wang X. Paclitaxel nanosuspensions coated with P-gp inhibitory surfactants: I. Acute toxicity and pharmacokinetics studies. Colloids Surf. B Biointerfaces 2013, 111:277-281.
25. Zhang J., Lv H., Jiang K., Gao Y. Enhanced bioavailability after oral and pulmonary administration of baicalein nanocrystal. Int. J. Pharm. 2011, 420:180-188.
26. Sahu B.P., Das M.K. Preparation and in vitro/in vivo evaluation of felodipine nanosuspension. Eur. J. Drug Metab. Pharmacokinet. 2014, 39:183-193.
27. Mou D., Chen H., Wan J., Xu H., Yang X. Potent dried drug nanosuspensions for oral bioavailability enhancement of poorly soluble drugs with pH-dependent solubility. Int. J. Pharm. 2011, 413:237-244.
28. Huang Y., Luo X., You X., Xia Y., Song X., Yu L. The preparation and evaluation of water-soluble SKLB610 nanosuspensions with improved bioavailability. AAPS PharmSciTech 2013, 14:1236-1243.
29. Xu Y., Wang Y., Li X.M., Huang Q., Chen W., Liu R., Chen B., Wei P. Study on the release of fenofibrate nanosuspension in vitro and its correlation with in situ intestinal and in vivo absorption kinetics in rats. Drug Dev. Ind. Pharm. 2014, 40:972-979.
30. Han M., Yu X., Guo Y., Wang Y., Kuang H., Wang X. Honokiol nanosuspensions: preparation, increased oral bioavailability and dramatically enhanced biodistribution in the cardio-cerebro-vascular system. Colloids Surf. B Biointerfaces 2014, 116:114-120.
31. Shi Y., Zou M., An Y., Ji Z., Gao P., Cheng G. A potent preparation method combining neutralization with microfluidization for rebamipide nanosuspensions and its in vivo evaluation. Drug Dev. Ind. Pharm. 2013, 39:996-1004.
32. Liu Y., Zhang D., Duan C., Jia L., Xie P., Zheng D., Wang F., Liu G., Hao L., Zhang X., Zhang Q. Studies on pharmacokinetics and tissue distribution of bifendate nanosuspensions for intravenous delivery. J. Microencapsulation 2012, 29:194-203.
33. Hao L., Luan J., Zhang D., Li C., Guo H., Qi L., Liu X., Li T., Zhang Q. Research on the in vitro anticancer activity and in vivo tissue distribution of Amoitone B nanocrystals. Colloids Surf. B Biointerfaces 2014, 117:258-266.
34. Gao Y., Li Z., Sun M., Li H., Guo C., Cui J., Li A., Cao F., Xi Y., Lou H., Zhai G. Preparation, characterization, pharmacokinetics, and tissue distribution of curcumin nanosuspension with TPGS as stabilizer. Drug Dev. Ind. Pharm. 2010, 36:1225-1234.
35. Agarwal V., Bajpai M. Preparation and optimization of esomeprazole nanosuspension using evaporative precipitation-ultrasonication. Trop. J. Pharm. Res. 2014, 13:497.
36. Tian X., Li H., Zhang D., Liu G., Jia L., Zheng D., Shen J., Shen Y., Zhang Q. Nanosuspension for parenteral delivery of a p-terphenyl derivative: preparation, characteristics and pharmacokinetic studies. Colloids Surf. B Biointerfaces 2013, 108:29-33.
37. Ali H.S.M., York P., Ali A.M.A., Blagden N. Hydrocortisone nanosuspensions for ophthalmic delivery: a comparative study between microfluidic nanoprecipitation and wet milling. J. Control. Release 2011, 149:175-181.
38. Liu G., Zhang D., Jiao Y., Guo H., Zheng D., Jia L., Duan C., Liu Y., Tian X., Shen J., Li C., Zhang Q., Lou H. In vitro and in vivo evaluation of riccardin D nanosuspensions with different hydrodynamic diameter. Colloids Surf. B Biointerfaces 2013, 102:620-626.
39. Xia D., Quan P., Piao H., Piao H., Sun S., Yin Y., Cui F. Preparation of stable nitrendipine nanosuspensions using the precipitation-ultrasonication method for enhancement of dissolution and oral bioavailability. Eur. J. Pharm. Sci. 2010, 40:325-334.
40. Zuo B., Sun Y., Li H., Liu X., Zhai Y., Sun J., He Z. Preparation and in vitro/in vivo evaluation of fenofibrate nanocrystals. Int. J. Pharm. 2013, 455:267-275.
41. Ganta S., Paxton J.W., Baguley B.C., Garg S. Formulation and pharmacokinetic evaluation of an asulacrine nanocrystalline suspension for intravenous delivery. Int. J. Pharm. 2009, 367:179-186.
42. Guo J.-j., Yue P.-F., Lv J.-l., Han J., Fu S.-s., Jin S.-x., Jin S.-y., Yuan H.-L. Development and in vivo/in vitro evaluation of novel herpetrione nanosuspension. Int. J. Pharm. 2013, 441:227-233.
43. Li Y., Wang Y., Yue P.-F., Hu P.-Y., Wu Z.-F., Yang M., Yuan H.-L. A novel high-pressure precipitation tandem homogenization technology for drug nanocrystals production-a case study with ursodeoxycholic acid. Pharm. Dev. Technol. 2014, 19:662-670.
44. Du B., Shen G., Wang D., Pang L., Chen Z., Liu Z. Development and characterization of glimepiride nanocrystal formulation and evaluation of its pharmacokinetic in rats. Drug Deliv. 2013, 20:25-33.
45. Wu L., Zhang J., Watanabe W. Physical and chemical stability of drug nanoparticles. Adv. Drug Deliv. Rev. 2011, 63:456-469.
46. Lu A.T., Frisella M.E., Johnson K.C. Dissolution modeling: factors affecting the dissolution rates of polydisperse powders. Pharm. Res. 1993, 10:1308-1314.
47. Higashino H., Hasegawa T., Yamamoto M., Matsui R., Masaoka Y., Kataoka M., Sakuma S., Yamashita S. In vitro-in vivo correlation of the effect of supersaturation on the intestinal absorption of BCS Class 2 drugs. Mol. Pharm. 2014, 11:746-754.
48. Jackson C.L., McKenna G.B. The melting behavior of organic materials confined in porous solids. J. Chem. Phys. 1990, 93:9002-9011.
49. Hintz R.J., Johnson K.C. The effect of hydrodynamic diameter distribution on dissolution rate and oral absorption. Int. J. Pharm. 1989, 51:9-17.
50. Khadka P., Ro J., Kim H., Kim I., Kim J.T., Kim H., Cho J.M., Yun G., Lee J. Pharmaceutical particle technologies: an approach to improve drug solubility, dissolution and bioavailability. Asian J. Pharm. Sci. 2014, 9:304-316.
51. Che E., Zheng X., Sun C., Chang D., Jiang T., Wang S. Drug nanocrystals: a state of the art formulation strategy for preparing the poorly water-soluble drugs. Asian J. Pharm. Sci. 2012, 7:85-95.